CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CCTG is proud to announce that the 2021 Founders Award was presented to Dr. Michael Crump this past weekend at the CCTG Spring Meeting. The Founder's Award is presented annually to an investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer. This award honours an Investigator whose excellence in clinical trials research has provided techniques, information or concepts that will direct the future of the oncology research community and CCTG.
Congratulations to these trial teams and their member centres for their efforts and dedication to the success of CCTG clinical trials, these recipients were announced at the 2021 CCTG Annual Spring Meeting of Participants last week.
Reporting to the Manager, Office of Compliance and Oversight (OCO), the Audit and Monitoring Group (AMG) Team Leader will lead one of the two teams in AMG, namely the Canadian On-Site Monitoring Team OR the Residual and International Monitoring Teams. The AMG Team Leader will ensure AMG standard operating procedures are followed to ensure compliance with applicable guidelines, regulations and standards.
The #CCTG2021 Virtual Spring Meeting is less than a month away!
The first round of invitations has been sent so check your inbox for your invitation email. If you cannot find your e-invitation in your inbox, please check your trash or spam folders. If you need to have your e-invitation re-sent please e-mail us at meeting.spring@ctg.queensu.ca.
Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.
Evaluate the ability to predict survival benefit from adjuvant chemotherapy in early stage non-small cell lung cancer (NSCLC), and
